Combined endostatin/sFlt-1 antiangiogenic gene therapy is highly effective in a rat model of HCC
10.1002/hep.20613
Saved in:
Main Authors: | Graepler, F., Verbeek, B., Graeter, T., Smirnow, I., Gregor, M., Lauer, U.M., Kong, H.L., Schuppan, D., Bauer, M., Vonthein, R. |
---|---|
Other Authors: | MEDICINE |
Format: | Article |
Published: |
2014
|
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/117595 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Pharmacokinetics of recombinant human endostatin in rats
by: Yang, X.-X., et al.
Published: (2014) -
Comparison of maternal serum PlGF and sFlt-1 between pregnancies with and without fetal hemoglobin Bart's disease
by: Fuanglada Tongprasert, et al.
Published: (2018) -
Comparison of maternal serum PlGF and sFlt-1 between pregnancies with and without fetal hemoglobin Bart's disease
by: Tongprasert F., et al.
Published: (2014) -
Comparison of maternal serum PlGF and sFlt-1 between pregnancies with and without fetal hemoglobin Bart's disease
by: Fuanglada Tongprasert, et al.
Published: (2018) -
Semaphorin-PlexinD1 Signaling Limits Angiogenic Potential via the VEGF Decoy Receptor sFlt1
by: Zygmunt, Tomasz, et al.
Published: (2021)